Education
About Us
Working with TipRanks
Follow Us
CG Oncology, Inc. (CGON)
NASDAQ:CGON
CGON Stock Chart & Stats
$42.98
-$0.55(-1.77%)
At close: 4:00 PM EST
$42.98
-$0.55(-1.77%)
Day’s Range― - ―
52-Week Range$14.80 - $45.56
Previous Close$30.46
Volume740.02K
Average Volume (3M)978.81K
Market Cap
$3.33B
Enterprise Value$1.32B
Total Cash (Recent Filing)$661.05M
Total Debt (Recent Filing)$994.00K
Price to Earnings (P/E)―
Beta1.75
Next Earnings
Nov 18, 2025EPS Estimate
-0.56Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-0.54
Shares Outstanding76,247,580
10 Day Avg. Volume797,100
30 Day Avg. Volume978,813
Financial Highlights & Ratios
PEG RatioN/A
Price to Book (P/B)N/A
Price to Sales (P/S)N/A
P/FCF RatioN/A
Enterprise Value/Market Cap0.40
Enterprise Value/Revenue2.40K
Enterprise Value/Gross Profit3.35K
Enterprise Value/Ebitda-8.41
Forecast
1Y Price Target
$70.00Price Target Upside62.87% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering13
Bulls Say, Bears Say
Bulls Say
Market OpportunityThe initial creto label and guidelines inclusion would encompass approximately 25,000 patients, offering a multi-billion-dollar opportunity available to CGON even when accounting for competitors.
Market PenetrationCGON's cretostimogene (creto, oncolytic virus) is likely to be rapidly adopted and could penetrate as much as 50% of the BCG-unresponsive market.
Regulatory ProgressThe regulatory work at CGON is progressing well as management expressed a high level of confidence.
Bears Say
CG Oncology, Inc. News
CGON FAQ
What was CG Oncology, Inc.’s price range in the past 12 months?
CG Oncology, Inc. lowest stock price was $14.80 and its highest was $45.56 in the past 12 months.
What is CG Oncology, Inc.’s market cap?
CG Oncology, Inc.’s market cap is $3.33B.
When is CG Oncology, Inc.’s upcoming earnings report date?
CG Oncology, Inc.’s upcoming earnings report date is Nov 18, 2025 which is in 18 days.
How were CG Oncology, Inc.’s earnings last quarter?
CG Oncology, Inc. released its earnings results on Aug 08, 2025. The company reported -$0.54 earnings per share for the quarter, missing the consensus estimate of -$0.466 by -$0.074.
Is CG Oncology, Inc. overvalued?
According to Wall Street analysts CG Oncology, Inc.’s price is currently Undervalued.
Does CG Oncology, Inc. pay dividends?
CG Oncology, Inc. does not currently pay dividends.
What is CG Oncology, Inc.’s EPS estimate?
CG Oncology, Inc.’s EPS estimate is -0.56.
How many shares outstanding does CG Oncology, Inc. have?
CG Oncology, Inc. has 76,247,580 shares outstanding.
What happened to CG Oncology, Inc.’s price movement after its last earnings report?
CG Oncology, Inc. reported an EPS of -$0.54 in its last earnings report, missing expectations of -$0.466. Following the earnings report the stock price went up 2.053%.
Which hedge fund is a major shareholder of CG Oncology, Inc.?
Currently, no hedge funds are holding shares in CGON
CG Oncology, Inc. Stock Smart Score
Neutral
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Strong Buy
Average Price Target:
$70.00 (62.87% Upside)
$70.00 (62.87% Upside)
Blogger Sentiment
Bullish
CGON Sentiment 100%
Sector Average ―
Sector Average ―
Hedge Fund Trend
Decreased
By 977.7K Shares
Last Quarter.
Last Quarter.
Insider Transactions
Bought Shares
Worth $47.2M over
the Last 3 Months
the Last 3 Months
Crowd Wisdom
Very Positive
Last 7 Days ▲ 0.8%
Last 30 Days ▲ 39.9%
Last 30 Days ▲ 39.9%
Technicals
SMA
Positive
20 days / 200 days
Momentum
17.21%
12-Months-Change
Fundamentals
Return on Equity
-20.95%
Trailing 12-Months
Asset Growth
24.30%
Trailing 12-Months
Company Description
CG Oncology, Inc.
CG Oncology Inc is a clinical biopharmaceutical company focused on developing and commercializing a potential backbone bladder-sparing therapeutic for patients afflicted with bladder cancer. Their product candidate cretostimogene, is initially in clinical development for the treatment of patients with high-risk Non-Muscle Invasive Bladder Cancer who are unresponsive to Bacillus Calmette Guerin (BCG) therapy, the current standard-of-care for high-risk NMIBC.
CGON Stock 12 Month Forecast
Average Price Target
$70.00
▲(62.87% Upside)
Technical Analysis
Cogent Biosciences
―
IDEAYA Biosciences
―
Arcutis Biotherapeutics
―
Beam Therapeutics
―
Disc Medicine
―
Ownership Overview
10.29% Insiders
22.70% Mutual Funds
0.09% Other Institutional Investors
53.06% Public Companies and
Individual Investors